The crystallizable fragment (Fc) region of Adintrevimab has a modification to extend its half-life. Adintrevimab binds to a distinct epitope in the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 that partially overlaps the angiotensin-converting enzyme 2 binding site and is highly conserved among sarbecoviruses. In vitro, Adintrevimab has demonstrated potent neutralizing activity against most variants and sublineages of SARS-CoV-2 (including Alpha, Beta, Gamma, and Delta) as well as other SARS-like viruses. Adintrevimab displays reduced in vitro activity against Omicron BA.1/BA.1.1 and lacks activity against BA.2, BA.3, BA.4, and BA.5[1].
Adintrevimab (9.25, 55, 333, or 2,000 μg; i.p.; once) provids protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner[1].
Adintrevimab (5-25 mg/kg; i.v.; once) provids protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner[1].
References:
[1]. Elizabeth E Zumbrun, et al. Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19. Antimicrob Agents Chemother. 2022 Dec 15;e0135322.